Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
PRIMARY OBJECTIVES:
Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD.
SECONDARY OBJECTIVES:
Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.